Series B Medtech Milestones: What Has to Be True Before You Raise

← Back to All Insights

Series B is where medtech companies prove they can move from "interesting product" to "investable platform." The transition is not about raising more money—it is about demonstrating that the milestones unlocked by the prior capital have de-risked the next stage enough to justify materially larger investment. Founders who approach Series B thinking it is Series A with a larger number consistently struggle.

Series B medtech investors have an unmistakable pattern: they evaluate operational evidence of post-clearance scalability, not just regulatory progress.

Regulatory Milestone Beyond Clearance

510(k) clearance alone is not a Series B milestone. What investors want to see: at least one product cleared, evidence of post-clearance commercial pull (initial customer wins, not just LOIs), a regulatory pipeline showing second and third products in development, and a clear path to indication expansion or international clearances within the Series B period.

Clinical Evidence at Scale

Pivotal trial data sufficient to support the lead indication is necessary but not sufficient. Series B investors want to see real-world data emerging post-clearance, comparative effectiveness data versus standard of care, and an evidence-generation strategy for the indications you plan to pursue with the new capital.

Commercial Traction Patterns

Specific traction signals: first 10-20 paying customers with documented use cases; gross margin expansion as manufacturing scales; commercial team productivity ramping consistent with the sales model; documented reasons for lost deals; expansion within initial customer accounts. The absolute revenue number matters less than the slope and the unit economics.

Manufacturing and Quality Maturity

By Series B, your QMS should be ISO 13485 certified, your manufacturing should have demonstrated capacity headroom of at least 3x current demand, and you should have validated at least two suppliers for every critical component. Series B investors will discover these gaps in diligence—addressing them post-money is much more expensive than addressing them pre-money.

Team Composition Signals

Series A often funds a founder-led team. Series B expects functional leadership: a VP Engineering or CTO whose background matches the scale challenge; a VP Sales whose track record predicts the GTM motion; a VP Quality / Regulatory who has navigated the next regulatory class up; a CFO or strong Director of Finance with healthcare or medical-device specific experience.

Capital Plan Sophistication

The Series B raise size should connect explicitly to the milestones required for Series C or to operating-cash-flow positivity. Vague "18-24 months of runway" pitches do not land in the current market. Specific milestone-tied tranches, contingent commercial KPIs, and explicit risk-adjusted scenarios are now table stakes.

Series B medtech raises succeed when the company can show that prior capital was deployed efficiently, the next-stage operational risk has been credibly reduced, and the team has the leadership depth to execute the post-Series-B plan. Founders who treat Series B as a regulatory milestone celebration tend to find the round longer and harder than expected. Founders who treat it as an operational maturity demonstration tend to close on terms they can live with.